FDA Accepts Supplemental Application for Malarone Pediatric
The FDA has accepted a supplemental application for Malarone Pediatric, containing atovaquone and proguanil hydrochloride.
Therapeutic Area
Therapeutic area intelligence for Antimalarial with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.